XHXiaodong He

Xiaodong He

*This is an algorithmically generated author record based on publicly available information.

Xiaodong He has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Rui Wang

    Deparment of Clinical Laboratory, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, China

    2 shared publications
  • Zuojun Shen

    Department of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China

    2 shared publications
  • Jie Hu

    Department of Clinical Laboratory, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China

    1 shared publication
  • Jing Wu

    Deparment of Clinical Laboratory, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei 230001, China

    1 shared publication
  • Peng Zhou

    Beijing Bohui Innovation Biotechnology, Changping District, Beijing 102200, China

    1 shared publication
  • Xiuhong Li

    Department of Clinical Laboratory, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China

    1 shared publication

Latest Publications

  • Open Access

    Expression Status and Prognostic Value of m6A RNA Methylation Regulators in Lung Adenocarcinoma

    by Xiuhong Li, Zian Feng, Rui Wang, Jie Hu, Xiaodong He, Zuojun Shen

    N6-methyladenosine (m6A) RNA modification is the most abundant modification method in mRNA, and it plays an important role in the occurrence and development of many cancers. This paper mainly discusses the role of m6A RNA methylation regulators in lung adenocarcinoma (LUAD) to identify novel prognostic biomarkers. The gene expression data of 19 m6A methylation regulators in LUAD patients and its relevant clinical parameters were extracted from The Cancer Genome Atlas (TCGA) database. We selected three significantly differentially expressed m6A regulators in LUAD to construct the risk signature, and evaluated its prognostic prediction efficiency using the receiver operating characteristic (ROC) curve. Kaplan–Meier survival analysis and Cox regression analysis were used to identify the independent prognostic significance of the risk signature. The ROC curve indicated that the area under the curve (AUC) was 0.659, which means that the risk signature had a good prediction efficiency. The results of the Kaplan–Meier survival analysis and Cox regression analysis showed that the risk score can be used as an independent prognostic factor for LUAD. In addition, we explored the differential signaling pathways and cellular processes related to m6A methylation regulators in LUAD.


  • Open Access

    A Sample-In-Answer-Out Microfluidic System for the Molecular Diagnostics of 24 HPV Genotypes Using Palm-Sized Cartridge

    by Rui Wang, Jing Wu, Xiaodong He, Peng Zhou, Zuojun Shen

    This paper proposes an automated microfluidic system for molecular diagnostics that integrates the functions of a traditional polymerase chain reaction (PCR) laboratory into a palm-sized microfluidic cartridge (CARD) made of polystyrene. The CARD integrates 4 independent microfluidic sample lanes, which can independently complete a sample test, and each sample lane integrates the 3 functional areas of the sample preparation area, PCR amplification area, and product analysis area. By using chemical cell lysis, magnetic silica bead-based DNA extraction, combined with multi-PCR-reverse dot hybridization with microarray, 24 HPV genotypes can be typing tested in CARD. With a custom-made automated CARD operating platform, the entire process can be automatically carried out, achieving sample-in-answer-out. The custom-made operation platform is developed based on a liquid handling station-type, which can automatically load off-chip reagents without placing reagents in CARD in advance. The platform can control six CARDs to work simultaneously, detect 24 samples at a time. The results show that the limit of detection of the microfluidic system is 200 copies/test, and the positive detection rate of clinical samples by this system is 100%, which is an effective method for detection of HPV.